Please assess the completion status of the following clinical trial:

Trial Title: Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females between the ages of 18 and 75 who are diagnosed with mild to moderate Crohn's disease (defined by a CDAI \[Crohn's Disease Activity Index\] score of 220 and 450)~* Normal lab parameters~* Are willing to give informed consent~* Have previously used and either were intolerant to or lost response to infliximab~Exclusion Criteria:~* History of certain types of cancer~* Diagnosis of ulcerative colitis~* Pregnant female or breast feeding subjects~* Known obstructive strictures~* Surgical bowel resection in the past 6 months~* History of listeria, human immunodeficiency virus (HIV), central nervous system demyelinating disease or untreated TB (tuberculosis)~* History of poorly controlled medical conditions~* Specific doses and durations of Crohn's medications~* Subjects that have previously used infliximab and have never clinically responded unless primary non-response was due to a treatment limiting reaction to infliximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).